On June 25, 2026 Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer, reported that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Harvey Briggs, Chief Communications Officer, Force Family Office. Joining them will be James Cardia, Ph.D., who will explore siRNA therapy and skin cancer treatments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to take part in this fireside chat with Force Family Office," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. "Dr. Jim Cardia will discuss the future direction of siRNA oncology and highlight how our INTASYL siRNA program represents a differentiated and innovative approach to immuno-oncology."

DATE: Monday June 29, 2026

TIME: 12 PM EDT

REGISTRATION LINK: PHIO Pharma – Force Family Office

(Press release, Phio Pharmaceuticals, JUN 25, 2026, View Source [SID1234668954])